A comprehensive review on immuno-nanomedicine for breast cancer therapy: Technical challenges and troubleshooting measures

Saravanakumar, Kandasamy; Sathiyaseelan, Anbazhagan; Usliyanage, Janandi Pujani; Naveen, Kumar Vishven; Wijesinghe, Udari; Hu, Xiaowen; Priya, V. Vishnu; Thiripuranathar, Gobika; Wang, Myeong‐Hyeon

doi:10.1016/j.intimp.2021.108433

Cited by 5 publications

(5 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with Herceptin®, the reference product, CT-P6 binds to the same HER2 epitope with great affinity and specificity (Genentech) [9,10]. In 2018, the Government Agency of Medicine in Europe and the US Food and Drug Administration approved CT-P6 to treat HER2-positive metastatic BC at their early stage [14][15][16]. Clinical trials are supplemented by real-world studies showing the long-term safety and efficacy of medications among a wider patient population, as well as in various settings and in conjunction with other treatments.…”

Section: Effectivenessmentioning

confidence: 99%

Biosimilar in Breast Cancer: A Narrative Review

Barman,

Bandyopadhyay,

Talukdar

2024

Cureus

View full text Add to dashboard Cite

Breast cancer (BC) has been identified as a major public health cancer as it topped the list of most prevalent cancers among women in the last three years. Rigorous research has been conducted to improve the prognosis of cancer therapies since the time of inception. Recent advancements in cancer therapy have introduced monoclonal biosimilars as a promising treatment alternative. Monoclonal antibodies (mAbs), produced through cloning, have demonstrated effectiveness in targeting diverse antigens. Biosimilar, considered complex entities compared to small-molecule drugs, pose challenges in replication due to their biological nature. The manufacturing process involves rigorous comparability testing to ensure similarity in quality, safety, and efficacy with the reference product. Trastuzumab biosimilars, such as CT-P6, Ontruzant®, ABP 980, and PF-05280014, have shown efficacy in treating HER2-positive metastatic BCs, presenting a viable alternative to the reference product. The implications of monoclonal biosimilars extend beyond trastuzumab, with bevacizumab emerging as another significant biosimilar for BC treatment. The shift toward biosimilar aims to enhance accessibility to biologics by reducing costs. Health economic analyses indicate potential cost savings, contributing to the overall cost-effectiveness of biosimilar adoption. While concerns about switching between reference products and biosimilars exist, evidence suggests a lower risk of immunogenicity-related side effects with mAbs like trastuzumab. Monoclonal biosimilars present a promising avenue in BC therapy, demonstrating efficacy, safety, and potential cost savings. The integration of biosimilars into cancer treatment strategies offers a means to improve accessibility to effective care while addressing economic considerations in healthcare.

show abstract

Section: Effectivenessmentioning

confidence: 99%

Biosimilar in Breast Cancer: A Narrative Review

Barman,

Bandyopadhyay,

Talukdar

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Hence, this characteristic enables they to form spherical particles containing an inner aqueous core immediately when combined with water (Alavi and Hamidi, 2019). Typically, liposomes range in size from 25nm to 2.5 μm with one or more bilayer membranes (Saravanakumar et al, 2022). This unique property of liposomes enables them to effectively load hydrophobic drugs in the lipid bilayer and encapsulate hydrophilic drugs in the internal aqueous core.…”

Section: Liposomesmentioning

confidence: 99%

“…Frontiers in Pharmacology frontiersin.org biocompatible polymers, that are comprised of ester, amide, ether and other functional groups (Juan et al, 2020). The PCL, PLA and poly (lactic-co-glycolic acid) (PLGA) are biocompatible polymers approved by FDA to be used in drug delivery and other polymers such as polyethylene glycol (PEG), chitosan (CS) and hyaluronic acid (HA) are used for drug delivery as well (Saravanakumar et al, 2022). Additionally, by adjusting the properties of the polymers or modifying the surface with various ligands, P-NPs target and control drugs release, thus improving the bioavailability and treatment effect (Zielinska et al, 2020).…”

Section: Figurementioning

confidence: 99%

“…The dendritic nanoparticle is composed of three parts, a central core, repeating branching units and outer surface functional group, with a size ranging from 1-100 nm (Kesharwani et al, 2022). Dendrimers are especially helpful for improving the solubility of hydrophobic drugs, because the core of dendrimers is usually hydrophobic (Saravanakumar et al, 2022). The branched structures of dendrimers have various modifications to choose from, so that high drug content and targeted drug delivery can be better achieved (Jain et al, 2010).…”

Section: Dendrimersmentioning

confidence: 99%

See 1 more Smart Citation

The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies

Yang

Dai

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequently diagnosed malignant tumor among women in the world. BC is the heterogeneous tumor with different subtypes including luminal A-like, luminal B-like (HER2-/HER2+), HER2 enriched, and triple-negative BC. The therapeutic strategies including surgery, chemotherapy, radiotherapy, targeted therapy, and endocrine therapy are well developed and commonly used in the treatment of BC. However, some adverse effects of these conventional treatments limited their wide application in clinical. Therefore, it is necessary to develop more safe and more efficient individualized treatment strategies of the BC. Nanomedicine, as the most promising strategy for controlled and targeted drug delivery, is widely used in multiple aspects of cancer therapy. Importantly, accumulative evidences show that nanomedicine has achieved good outcomes in the treatment of BC and a huge amount of BC patients benefited from the nanomedicine related treatments. In this review, we summarized and discussed the major problems occurred during the administration of conventional treatment strategies for BC and the potential roles of nanomedicine in promoting the treatment efficacy of BC by overcoming obstacles of current treatment of BC.

show abstract

“…After the diagnosis of breast cancer, a variety of possible treatments are considered depending on the patient's condition [8,9], including surgery, chemotherapy, and radiotherapy, which are all costly, have side effects, reduce quality of life, and often lead to other health-related problems [10,11]. Therefore, it is necessary to introduce new readily available drugs with fewer side effects and availability used against a wider range of cancers.…”

Section: Introductionmentioning

confidence: 99%